DNA
Ginkgo Bioworks Holdings, Inc.
NYSE · Healthcare · Biotechnology · US
$6.95
+0.00%Year over year
Reported trailing growth
- Revenue
- -51.5%
- EBITDA
- +28.6%
- EBIT
- +7.2%
- EPS
- +15.3%
- Free cash flow
- +30.7%
- Operating cash flow
- +28.4%
Forward estimates
Based on analyst estimates
- Revenue
- -23.0%
- EBITDA
- -27.5%
- EPS
- +0.0%
Three-year CAGR
- Revenue
- -29.1%
- EBITDA
- +47.4%
- EBIT
- +43.7%
- Net income
- +42.8%
- EPS
- +46.5%
- Free cash flow
- +53.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026